CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib, which help slow cancer cell division. Immunotherapy: For some patients with triple-negative breast cancer (which lacks hormone receptors ...

A nurse practitioner discusses ASCO’s recommendations of CDK4/6 inhibitors—namely abemaciclib and ribociclib—in certain high-risk breast cancer settings.

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the ...

Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

Atossa Therapeutics has strong financials with $79.5 million in cash and a cash runway of 13-14 quarters, minimizing ...

Tango Therapeutics (TNGX) announced an update on its PRMT5 program. Based on data from the dose escalation and early dose expansion cohorts of ...

On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be ...

The Alliance for Patient Access today announced the launch of the COPD Action Alliance, a national advocacy coalition that ...

Six/UW/Seattle Children’s Cancer Consortium scientists received new funding from the Breast Cancer Research Foundation to ...

Among the many impactful sessions, a symposium titled ‘Incorporating Novel Treatment Insights for Estrogen Receptor-Positive (ER+) Early Breast Cancer Patients’ garnered particular attention.